Table 1.
Study | Participants/Data Collection | Inclusion | Exclusion | Pubertal Staging |
---|---|---|---|---|
Energy Balance in Non-obese Children with Down Syndrome | Down syndrome n = 24 Typically developing n = 33 Age 3–13 years Longitudinal data collected at visit 0, 12, 24, and 36 months. Multiple observations per subject. 2001 to 2005 |
At least two prepubertal children per family at enrollment.
|
Other significant chronic conditions affecting growth or energy balance | Prepubertal status confirmed at baseline via parental assisted, self-assessment questionnaire(Morris and Udry, 1980) |
Down Syndrome Metabolic Health Study | Down syndrome n = 35 Age 10–20 years Single visit 2013 |
Down syndrome | Major organ system illness (except type 2 diabetes mellitus) Cyanotic congenital heart disease Pulmonary hypertension Pregnancy Genetic syndrome known to affect glucose tolerance Familial hypercholesterolemia |
Physical exam by pediatric endocrinologist |
Reference Project on Skeletal Development | n = 802 Age 5–19 years Single visit 2000 to 2007 |
Healthy, typically developing child Age ≥ 5 years |
History of illness or medication use that may affect growth, nutritional status, or pubertal development | Pubertal status confirmed at baseline via validated self-assessment questionnaire(Morris and Udry, 1980) |
Glucocorticoid Induced Osteopenia in Children | Nephrotic syndrome n = 67 Crohn disease n =128 Longitudinal data collected at visit 0, 6, and 12 months. Multiple observations per subject. 2001–2005 |
Age 5 – 21 years Steroid sensitive nephrotic syndrome according to ISKDC criteria, treated at CHOP. Newly diagnosed or prevalent biopsy-proven CD |
Decreased renal function Any history of a condition or treatment affecting bone health, growth and nutrition, unrelated to nephrotic syndrome or Crohn disease |
Pubertal status confirmed at baseline via validated self-assessment questionnaire(Morris and Udry, 1980) |
n, number of participants CHOP, The Children’s Hospital of Philadelphia